enGene Therapeutics Inc.

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ENGN and other ETFs, options, and stocks.

About ENGN

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

CEO

Ronald Harold Wilfred Cooper

CEORonald Harold Wilfred Cooper

Employees

Employees82

Headquarters

Saint-Laurent, Québec

HeadquartersSaint-Laurent, Québec

Founded

2023

Founded2023

Employees

Employees82

ENGN Key Statistics

Market cap

537.59M

Market cap537.59M

Price-Earnings ratio

-3.54

Price-Earnings ratio-3.54

Dividend yield

—

Dividend yield—

Average volume

327.31K

Average volume327.31K

High today

$8.19

High today$8.19

Low today

$7.69

Low today$7.69

Open price

$8.02

Open price$8.02

Volume

222.22K

Volume222.22K

52 Week high

$12.25

52 Week high$12.25

52 Week low

$2.65

52 Week low$2.65

Stock Snapshot

enGene Therapeutics Inc.(ENGN) stock is priced at $7.99, giving the company a market capitalization of 537.59M. It carries a P/E multiple of -3.54.

During the trading session on 2026-04-25, enGene Therapeutics Inc.(ENGN) shares reached a daily high of $8.19 and a low of $7.69. At a current price of $7.99, the stock is +3.9% higher than the low and still -2.4% under the high.

Trading activity shows a volume of 222.22K, compared to an average daily volume of 327.31K.

Over the past 52 weeks, enGene Therapeutics Inc.(ENGN) stock has traded between a high of $12.25 and a low of $2.65.

Analyst ratings

92%

of 13 ratings

Buy

92.3%

Hold

7.7%

Sell

People also own

Based on the portfolios of people who own ENGN. This list is generated using Robinhood data, and it’s not a recommendation.